E

    Equillium Inc (EQ)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.27
    -0.12 (-5.02%)

    Market Cap: $151.54M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    56%(18/32)
    Avg Surprise
    +6.30%
    Streak
    1 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.05
    Range$-0.06 - $-0.04
    7 analysts
    EPS Revisions
    1
    0
    7d
    1
    2
    30d
    EPS Estimate Drift
    90d ago$-0.05+9.1%
    60d ago$-0.05+2.7%
    30d ago$-0.05+0.2%
    7d ago$-0.05+0.2%
    Current$-0.05
    Revenue Consensus
    $0
    Range$0 - $0
    9 analysts
    Dec 31, 2026
    EPS Consensus$-0.05
    Range$-0.06 - $-0.01
    7 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    9 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.05---
    Sep 26EST
    		-$-0.05---
    Jun 26
    		$-0.04$-0.05+20.00%Beat+75.0%
    Mar 26
    		$-0.06$-0.04-50.00%Miss+75.0%
    Dec 25
    		$-0.04$-0.07+42.86%Beat+75.0%
    Sep 25
    		$-0.06N/A+72.73%Beat-29900.0%
    Jun 25
    		$-0.16$-0.18+11.11%Beat-1700.0%
    Mar 25
    		$-0.24$-0.33+27.27%Beat-200.0%
    Dec 24
    		$-0.16$-0.31+48.39%Beat-128.6%
    Sep 24
    		$-0.00N/A-100.14%Miss+99.8%
    Jun 24
    		$0.01N/A+107.69%Beat+110.0%
    Mar 24
    		$-0.08$-0.11+27.27%Beat+27.3%
    Dec 23
    		$-0.07N/A+58.82%Beat-187.5%
    Sep 23
    		$-0.11$-0.12+8.33%Beat+72.5%
    Jun 23
    		$-0.10$-0.11+9.09%Beat+75.6%
    Mar 23
    		$-0.11$-0.06-83.33%Miss+90.6%
    Dec 22
    		$0.08$-0.03+366.67%Beat+122.2%
    Sep 22
    		$-0.40$-0.37-8.11%Miss-14.3%
    Jun 22
    		$-0.41$-0.40-2.50%Miss-32.3%
    Mar 22
    		$-1.17$-0.38-207.89%Miss-254.5%
    Dec 21
    		$-0.36$-0.34-5.88%Miss+0.0%
    Sep 21
    		$-0.35$-0.34-2.94%Miss-12.9%
    Jun 21
    		$-0.31$-0.32+3.13%Beat+16.2%
    Mar 21
    		$-0.33$-0.32-3.13%Miss+26.7%
    Dec 20
    		$-0.36$-0.40+10.00%Beat+18.2%
    Sep 20
    		$-0.31$-0.44+29.55%Beat+11.4%
    Jun 20
    		$-0.37$-0.44+15.91%Beat-5.7%
    Mar 20
    		$-0.45$-0.41-9.76%Miss-32.4%
    Dec 19
    		$-0.44$-0.39-12.82%Miss-41.9%
    Sep 19
    		$-0.35$-0.42+16.67%Beat-12.9%
    Jun 19
    		$-0.35$-0.41+14.63%Beat-150.0%
    Mar 19
    		$-0.34$-0.30-13.33%Miss-
    Dec 18
    		$-0.31$-0.29-6.90%Miss-
    Sep 18
    		$-0.31$-0.11-181.82%Miss-
    Jun 18
    		$-0.14$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-11.35EV/EBITDA0.07x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-59.00%ROIC-26.68%
    Financial Health
    Debt/Equity0.01xInterest CoverageN/A
    Current Ratio23.40xQuick Ratio23.40x
    Trading Statistics
    Beta1.81Avg Volume483.25K
    52-Week High$3.5452-Week Low$0.76

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$2.31
    SMA 20$2.26
    SMA 50$2.54
    SMA 200$1.96
    EMA 10$2.31
    EMA 20$2.32
    EMA 50$2.41
    EMA 200$2.06

    MACD

    Line: -0.04Signal: -0.06Hist: 0.03

    ADX

    ADX: 14.8+DI: 21.4-DI: 19.8

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down56.0
    PSAR$2.53

    Bollinger Bands

    Upper Band$2.50
    Lower Band$2.02
    %B Position2103%(Upper)
    Band Width0.52

    RSI (14-Day)

    Neutral
    46.7

    Momentum Oscillators

    Stoch %K69.5
    Stoch %D68.9
    Williams %R-47.5
    ROC (10d)-8.5%
    Momentum-0.21
    CCI (20d)21.9
    MFI (14d)49.1

    Volatility Measures

    ATR (14d)$0.20(8.7%)
    StdDev (20d)0.12
    Hist Vol90.2%(High)

    Volume Flow

    VWAP$2.29
    OBV470.9M
    AD Line-245.1M
    CMF (20d)-0.033

    Volume Metrics

    Avg Vol (20d)481.2K
    Vol Ratio0.6x
    VWMA (20d)$2.25

    Pivot Points

    R3$2.59
    R2$2.52
    R1$2.46
    Pivot Point$2.39
    S1$2.33
    S2$2.26
    S3$2.20

    Advanced Oscillators

    TSI-5.62
    Ultimate Osc45.3
    KST-75.59

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total RevenueN/A$0$0$0$0$0$4.39M$12.16M$13.85M$10.69M$9.21M$8.87M
    Cost of RevenueN/A$24,000$23,000$28,000$32,000$33,000$35,000$35,000$35,000$32,000$33,000$31,000
    Gross ProfitN/A$-24,000$-23,000$-28,000$-32,000$-33,000$4.39M$12.16M$13.85M$10.66M$9.18M$8.87M
    Operating Expenses$5.16M$5.59M$3.94M$4.58M$6.20M$8.87M$9.09M$12.84M$13.95M$13.45M$12.38M$12.49M
    R&D$2.75M$2.99M$1.54M$1.30M$4.08M$5.92M$7.32M$9.56M$10.81M$9.74M$9.18M$8.97M
    SG&A$2.41M$2.62M$2.43M$3.27M$2.15M$2.95M$1.77M$3.28M$3.15M$3.74M$3.23M$3.52M
    Operating Income$-5,155,000$-5,610,000$-3,962,000$-4,575,000$-6,228,000$-8,870,000$-4,698,000$-679,000$-100,000$-2,791,000$-3,200,000$-3,623,000
    Interest Income$0$309,000$303,000$235,000$122,000$173,000$239,000$331,000$371,000$439,000$517,000$551,000
    Interest Expense$0$0$0$0$0$0$0$0$0$0$982,000$0
    Income Before Tax$-4,693,000$-5,311,000$-3,775,000$-4,230,000$-5,739,000$-8,654,000$-5,433,000$-7,000$468,000$-2,734,000$-2,326,000$-3,214,000
    Income Tax Expense$0$0$0$0$0$0$361,000$0$0$-11,276$16,000$496,000
    Net Income$-4,693,000$-5,311,000$-3,775,000$-4,230,000$-5,739,000$-8,654,000$-5,794,000$-7,000$468,000$-2,734,000$-2,342,000$-3,710,000
    EBITDA$-5,108,000$-5,287,000$-3,752,000$-4,202,000$-5,707,000$-8,621,000$-5,398,000$28,000$503,000$-2,702,000$-2,293,000$-3,183,000
    EBITN/A$-5,311,000$-3,775,000$-4,230,000$-5,739,000$-8,654,000$-5,433,000$-7,000$468,000$-2,734,000$-2,326,000$-3,214,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about EQ

    News

    Equillium | SCHEDULE 13G: Others

    This article is a SCHEDULE 13G filing for Equillium, indicating that an "Others" category of investor has submitted this regulatory document. The content of the filing itself is not provided, only the document type.

    Moomoo•8/24/26•
    Neutral

    EQ | Equillium, Inc. Common Stock Financials - Revenue Breakdown

    This article provides a financial overview of Equillium, Inc. (EQ), focusing on its revenue breakdown. It indicates that there is no specific revenue data by segment or geography currently available for the company. The page also details various financial metrics, insider trading activity, institutional holdings, analyst ratings, and corporate information for Equillium.

    Quiver Quantitative•8/23/26•
    Neutral

    Equillium (NASDAQ:EQ) Rating Increased to Hold at Wall Street Zen

    Wall Street Zen has upgraded Equillium (NASDAQ:EQ) from a "sell" to a "hold" rating, though the broader analyst consensus remains a "Moderate Buy" with an average price target of $7.57. Equillium shares opened at $2.36, and the company recently reported a quarterly loss of $0.04 per share, beating estimates. Insider selling totaled approximately $1.22 million over the last three months, while institutional investors now own 27.05% of the company.

    MarketBeat•8/15/26•
    Somewhat-Bullish

    Oppenheimer Maintains Equillium(EQ.US) With Buy Rating, Maintains Target Price $7

    Oppenheimer has reiterated its Buy rating for Equillium (EQ.US) and maintained its target price at $7. This indicates continued confidence from the firm in the company's prospects.

    Moomoo•8/14/26•
    Bullish

    Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

    Equillium, Inc. reported its second-quarter 2026 financial results, highlighting progress in advancing EQ504, a potent and selective aryl hydrocarbon receptor (AhR) modulator, toward clinical trials. The company expects to initiate a Phase 1 proof-of-mechanism study for EQ504 in Q4 2026, with data anticipated approximately six months later. Equillium also announced cash and cash equivalents of $57.2 million, projected to fund operations into 2029.

    GlobeNewswire•8/14/26•
    Somewhat-Bullish

    Frequently Asked Questions About EQ

    Does EQ pay dividends?
    Equillium Inc (EQ) does not currently pay a regular dividend.
    What is EQ's market cap?
    Equillium Inc (EQ) has a market capitalization of $151.54M with a current stock price of $2.27.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In